|  |
 |
 |
 |
|
 |
||
The Company is in Phase I/II clinical trials with Salirasib for pancreatic
cancer at Johns Hopkins and has initiated a Phase II clinical trial for
lung cancer at Memorial Sloan-Kettering Cancer Center. FDA grants Orphan-Drug
designation for Salirasib for the treatment of pancreatic cancer. Concordia has accepted the United States Adopted Names Council's (USAN)
proposed name of salirasib as the USAN for FTS. A new stem, "rasib" was
established to indicate the first RAS inhibitor. |
By exploiting the differences between cancer cells and normal
cells, Salirasib can inhibit the growth of malignant cells without
damaging healthy cells. |
|
|
||
Site by mebDESIGN